Chlorogenic Acid Isomer Composition to Reduce Metabolic Treatment Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional small molecule therapies for metabolic disorders, such as metformin, statins, and anti-obesity drugs, pose significant side effects and are contraindicated for certain patient populations, necessitating a safer alternative.

Innovation Solution

A chlorogenic acid composition comprising specific ratios of 3-CQA, 5-CQA, 4-CQA, 3,4-diCQA, 3,5-diCQA, and 4,5-diCQA is developed to inhibit enzymes like alpha-glucosidase, alpha-amylase, and lipase, while activating AMPK and reducing PPAR and CEBP expression, offering a safer treatment option.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional small molecule therapies (metformin, statins, anti-obesity drugs) are used to treat metabolic disorders, then therapeutic efficacy is improved, but harmful side effects increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter from synthetic small molecules to natural chlorogenic acid compounds, specifically using a mixture of chlorogenic acid isomers (5-CQA, 3-CQA, 4-CQA, and their dicaffeoyl derivatives) to achieve therapeutic effects with reduced toxicity and side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention uses a composite composition of multiple chlorogenic acid isomers in specific ratios (5-CQA: 3-20%, 3-CQA: 10-30%, 4-CQA: 10-30%, dicaffeoyl chlorogenic acids: 10-40%) to synergistically improve therapeutic efficacy while minimizing side effects

Inventive Principle:

Principle #40Composite materials

2Reliability

If metformin is administered to patients with contraindications (kidney disorders, liver disease, heart failure), then diabetes treatment is achieved, but risk of lactic acidosis increases

Engineering Contradiction:

Improvediabetes treatmentVSAvoidlactic acidosis risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces metformin with chlorogenic acid composition that acts as a safer alternative for patients who cannot tolerate metformin, effectively substituting a harmful treatment with a benign one for contraindicated populations

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

Chlorogenic acid serves as an intermediary therapeutic agent that achieves diabetes treatment goals without triggering the lactic acidosis pathway associated with metformin, particularly in patients with compromised organ function

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If anti-obesity drugs are used to reduce weight, then weight control is improved, but severe side effects occur

Engineering Contradiction:

Improveweight controlVSAvoidsevere side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the potentially harmful mechanism of anti-obesity drugs into a beneficial effect by using chlorogenic acid to inhibit lipase and alpha-glucosidase enzymes, reducing fat and carbohydrate absorption in a manner that mimics safe natural processes rather than forcing physiological changes

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

4Reliability

If statins are administered to treat dyslipidemia, then cardiovascular disease risk is reduced, but muscle damage and liver enzyme abnormalities occur

Engineering Contradiction:

Improvecardiovascular disease preventionVSAvoidmuscle damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the therapeutic approach from HMG-CoA reductase inhibition (statins) to direct enzyme inhibition of lipase and alpha-glucosidase by chlorogenic acid, achieving lipid and glucose control through a different biochemical pathway that avoids statin-related muscle and liver toxicity

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The chlorogenic acid composition effectively treats metabolic disorders with reduced side effects, including diabetes, obesity, and dyslipidemia, even in patients contraindicated for traditional therapies, by modulating enzyme activity and improving metabolic parameters.

Implementation Method 1

the inventor observed that his composition inhibits alpha-glucosidase, alpha-amylase and lipase

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 2

the inventive composition activates AMPK and reduces PPAR and CEBP expression

Methodology Applied

Scientific EffectSignal transduction:

Data Source

PatentUS12370164B2Chlorogenic acid composition for promoting a healthy body weight

Publication Date: 2025.07.29 VIDYA HERBS INC

AI summary

A composition of chlorogenic acids and method of its use and manufacture in the treatment of metabolic disorders. The composition can be obtained from sunflower seed extract, including Helianthus annulus seeds.